万孚生物(300482) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY 116,946,827.17, up 39.79% year-on-year[8] - Operating revenue for the period was CNY 566,457,918.59, representing a 24.15% increase compared to the same period last year[8] - Basic earnings per share increased to CNY 0.35, a rise of 40.00% year-on-year[8] - The company reported a net profit growth of 95.04% for the year-to-date period, totaling CNY 565,944,831.91[8] - The total operating revenue for the current period is CNY 2,173,091,511.35, an increase from CNY 1,424,073,483.06 in the previous period[67] - The net profit attributable to the parent company is CNY 116,946,827.17, compared to CNY 83,661,000.50 in the previous period, reflecting a growth of approximately 39.9%[59] - The total profit for the current period is CNY 132,725,553.12, an increase from CNY 105,302,681.78 in the previous period[59] - The total comprehensive income for the current period is CNY 111,288,419.66, compared to CNY 93,031,855.58 in the previous period[59] Assets and Liabilities - Total assets reached CNY 4,220,003,916.12, an increase of 43.34% compared to the previous year[8] - The company's total liabilities increased to ¥1,198,985,278.73 from ¥483,451,300.54, marking a significant rise of 148.1%[40] - The total assets of the company reached ¥4,220,003,916.12, up from ¥2,944,004,224.76 at the end of 2019, representing a growth of 43.3%[36] - The total liabilities were CNY 1,097,888,807.47, compared to CNY 378,324,547.66, which is an increase of approximately 190.5%[50] - The company's equity attributable to shareholders of the parent company increased to CNY 2,893,404,560.72 from CNY 2,305,811,926.35, reflecting an increase of approximately 25.5%[50] Cash Flow - The net cash flow from operating activities showed a significant increase of 425.91% compared to the previous year[8] - Cash inflow from financing activities reached ¥699,619,126.95, significantly higher than ¥144,408,740.92, marking an increase of about 384.5%[85] - Net cash flow from operating activities amounted to ¥711,362,137.81, compared to ¥135,264,219.30 in the previous period, reflecting a growth of over 426%[83] - The ending cash and cash equivalents balance stood at ¥1,581,059,544.07, a substantial increase from ¥221,791,963.54, reflecting a growth of approximately 612%[85] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,448[12] - The top ten shareholders collectively held 36.08% of the company's total shares[12] Research and Development - Research and development expenses for the quarter were CNY 65,124,998.65, up from CNY 41,650,950.64, representing a growth of about 56.4%[53] - Research and development expenses rose to ¥168,111,708.60, which is an increase of 97.3% from ¥85,177,656.25 in the previous period[77] Other Financial Metrics - The weighted average return on equity was 5.05%, up from 1.04% in the previous year[8] - The company received government subsidies amounting to CNY 17,023,802.65 during the reporting period[8] - The company reported a decrease in other comprehensive income, with a loss of CNY 6,016,778.71 compared to a loss of CNY 4,354,957.07 in the previous period[43] - The company reported a decrease in investment income, with a loss of ¥1,902,599.35 compared to a loss of ¥3,213,859.13 in the previous period[74]